Kanamycin Inj Rx
Generic Name and Formulations:
Kanamycin sulfate 500mg/vial, 1g/vial; soln for IM inj or IV infusion, intraperitoneal, nebulization, irrigation after dilution; contains sulfites.
Various generic manufacturers
Indications for Kanamycin Inj:
Short-term treatment of serious susceptible infections.
Adults and Children:
Obesity: base dose on lean body mass. IM: inject into upper outer quadrant of gluteal muscle. 15mg/kg/day in divided doses every 12 hours; or 15mg/kg/day in divided doses every 6–8 hours if continuously high blood levels desired. IV: infuse slowly over 30–60 mins; 15mg/kg/day in 2–3 divided doses. Usual duration: 7–10 days. Intraperitoneal, nebulization, irrigation: see literature. All routes: max 1.5g/day. Renal impairment: adjust dose based on serum levels or reduce frequency; see literature.
Monitor for nephro- and neurotoxicity; avoid peak serum levels >35micrograms/mL and trough levels >10micrograms/mL. Discontinue or adjust dose if auditory, vestibular, or renal dysfunction develops; monitor serum levels periodically. Monitor BUN, CrCl, serum creatinine levels before, frequently during, and after therapy. Perform audiogram in high-risk patients. Maintain adequate hydration. Prolonged use or excessive doses. Asthma. Muscular disorders (eg, myasthenia gravis, parkinsonism, or infant botulism). Elderly. Premature or neonatal infants. Pregnancy (Cat.D), nursing mothers: not recommended.
Avoid concomitant furosemide, ethacrynic acid, mannitol. Diuretics may increase toxicity. Increased risk of neurotoxicity and/or nephrotoxicity with concurrent or sequential polymyxin B, colistin, amphotericin B, other nephrotoxic or neurotoxic drugs; avoid. May potentiate neuromuscular blockade, respiratory paralysis with anesthetics, neuromuscular blockers. May be antagonized by concomitant penicillins, cephalosporins.
Nephro- or ototoxicity, neurotoxicity, neuromuscular blockade (eg, muscular paralysis, apnea), local irritation or pain; rare: rash, drug fever, headache, GI upset, paresthesia.
Formerly known under the brand name Kantrex.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Expert Roundtable: AHA Update on Dietary Fat Intake and CVD Risk
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation